Research

Hormonal

GLP-1 receptor agonists (e.g., liraglutide) produce significant weight loss (mean 8.4 kg over 56 weeks) by slowing gastric emptying and activating central satiety pathways, with 33.1% of patients achieving >10% body weight loss.

If you have obesity (BMI > 30, or > 27 with health issues), ask your doctor about GLP-1 agonists like liraglutide. This medication, taken daily, has been shown in clinical trials to help patients lose an average of 8.4 kg over a year, with many losing over 10% of their body weight. It works by slowing digestion and signaling fullness to your brain.

GoodSupportsHIGH confidence
A multicenter RCT evaluating daily 3 mg liraglutide administration in overweight/obese participants (BMI > 27 kg/m2 with comorbidities or > 30 kg/m2) reported 8.4 kg mean weight reduction over 56 weeks, with 33.1% achieving > 10% body weight loss [74].
Yue Kong et al. · Molecular Biomedicine · 2025

Why this rating

Cites a multicenter RCT, which is high-quality evidence, though it is a review paper summarizing it.

Source

Obesity: pathophysiology and therapeutic interventions

Yue Kong et al. · Molecular Biomedicine · 2025

DOI 10.1186/s43556-025-00264-9

narrative_reviewCited 44×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →